Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Zillow Group Inc Class C (Z) Price & Performance

Bristol-Myers Squibb CoTrade
Zillow Group Inc Class CTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Zillow Group Inc Class C — how do they compare? Bristol-Myers Squibb Co trades at $63.97 (market cap $129.94B), while Zillow Group Inc Class C trades at $33.07 (market cap $7.68B). The key difference: Bristol-Myers Squibb Co is far larger — about 16.9× Zillow Group Inc Class C's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.

BMYZ
Market Cap
$129.94B$7.68B
Sector
HealthMedia
52-Week High
$65.89$90.35
52-Week Low
$42.60$29.41
Enterprise Value
$163.92B$7.56B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

Zillow Group Inc Class C

Zillow Group (Z) trades at $33.10, down 1.93% on the day, with a bearish technical signal and mixed earnings history. Revenue growth is solid, rising to $2.58B in 2025, but profitability remains thin with a net margin of 1.96%. The stock faces headwinds from a securities class action lawsuit and a challenging real estate market, though analyst consensus points to significant upside with a $52 price target.

The outlook is cautious due to legal risks and weak near-term profitability, but long-term monetization potential and analyst optimism suggest opportunity if execution improves. Key risks include litigation outcomes and market volatility, while institutional sentiment leans neutral with a 50% hold rating.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Zillow Group Inc Class C

Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.

Read more on Z